|Day Low/High||111.15 / 113.30|
|52 Wk Low/High||96.04 / 126.07|
CEO Alex Gorsky dishes a bit on Monday's meeting with President Trump during Johnson & Johnson's conference call.
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may be worth buying.
Stocks move higher on Tuesday morning as earnings winners DuPont and Alibaba outpace weaker reports from the likes of Lockheed Martin.
There are many moving parts to J&J's latest earnings.
Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.
Stock futures are little changed on Tuesday morning as a rush of earnings reports leaves Wall Street torn on which direction to go.
The Fed's words can cause just as much volatility in the markets as the president's.
European stocks are expected to open firmer Tuesday as investors head into a busy corporate earnings season amid questions over the stability of economic policies from President Donald Trump.
Ethicon announces 510(k) clearance of the ECHELON FLEX™ GST SYSTEM (45mm)
Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.
Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.
The weak companies could be clobbered.
Complements and expands Ethicon's advanced energy portfolio with broad range of innovative electrosurgical tools
After an up-and-down year, this household name is as strong as ever.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.
Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.
A final deal could come as soon as this month, Bloomberg reported.
While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.
Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.
Animal health and oncology deal activity is heating up in 2017.